The global market for Modulators of the Genital System and Sex Hormones shows significant variations across countries in terms of sales per capita, expressed in PPP USD. Iceland leads the market with USD 18.2, followed by Ireland at USD 17, and Canada at USD 15.4. Notably, the year-on-year growth in 2023 was highest in Ireland (14.34%) and Australia (3.76%), whereas Canada and Finland experienced declines of -3.6% and -2.21%, respectively. Over the last five years, the CAGR highlights varying trends, with Iceland and Belgium showing consistent growth and countries like Canada and Slovenia experiencing slight downturns.
Future trends to watch include potential market expansions in emerging economies, increasing healthcare investments, and technological advancements in hormone treatments. Anticipated regulatory changes and demographic shifts, particularly aging populations, are also likely to significantly impact sales and demand dynamics globally.
Top countries in Modulators of the Genital System and Sex Hormones Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Iceland | 18.2 | 2023 | +2.25% | +3.26% | View data |
| 2 | 2 Ireland | 17 | 2023 | +15.65% | +14.34% | View data |
| 3 | 3 Canada | 15.4 | 2023 | -1.28% | -3.6% | View data |
| 4 | 4 Belgium | 13.1 | 2023 | 0% | +1.43% | View data |
| 5 | 5 Sweden | 11.3 | 2023 | +0.89% | +2.07% | View data |
| 6 | 6 Portugal | 11.2 | 2023 | +1.82% | +1.49% | View data |
| 7 | 7 Norway | 11.1 | 2023 | +12.12% | +0.18% | View data |
| 8 | 8 Finland | 11 | 2023 | 0% | -2.21% | View data |
| 9 | 9 Australia | 8.9 | 2023 | +2.3% | +3.76% | View data |
| 10 | 10 Luxembourg | 8.5 | 2023 | 0% | +0.24% | View data |
